These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Isoniazid pharmacokinetics-pharmacodynamics in an aerosol infection model of tuberculosis. Jayaram R; Shandil RK; Gaonkar S; Kaur P; Suresh BL; Mahesh BN; Jayashree R; Nandi V; Bharath S; Kantharaj E; Balasubramanian V Antimicrob Agents Chemother; 2004 Aug; 48(8):2951-7. PubMed ID: 15273105 [TBL] [Abstract][Full Text] [Related]
9. A facile one-step jet-milling approach for the preparation of proliposomal dry powder for inhalation as effective delivery system for anti-TB therapeutics. Srichana T; Eze FN; Thawithong E Drug Dev Ind Pharm; 2022 Oct; 48(10):528-538. PubMed ID: 36214588 [TBL] [Abstract][Full Text] [Related]
10. Mouse model for efficacy testing of antituberculosis agents via intrapulmonary delivery. Gonzalez-Juarrero M; Woolhiser LK; Brooks E; DeGroote MA; Lenaerts AJ Antimicrob Agents Chemother; 2012 Jul; 56(7):3957-9. PubMed ID: 22547626 [TBL] [Abstract][Full Text] [Related]
11. Moxifloxacin (BAY12-8039), a new 8-methoxyquinolone, is active in a mouse model of tuberculosis. Miyazaki E; Miyazaki M; Chen JM; Chaisson RE; Bishai WR Antimicrob Agents Chemother; 1999 Jan; 43(1):85-9. PubMed ID: 9869570 [TBL] [Abstract][Full Text] [Related]
13. Location of Pulmonary Mycobacteria Tuberculosis and Effectiveness of Various Dextrazide Compositions in Treatment of Mice with BCG-Induced Granulomatosis. Sinyavskaya AM; Shkurupy VA; Troitskiy AV; Kovner AM Bull Exp Biol Med; 2020 May; 169(1):63-66. PubMed ID: 32495171 [TBL] [Abstract][Full Text] [Related]
14. PA-824 is as effective as isoniazid against latent tuberculosis infection in C3HeB/FeJ mice. Dutta NK; Karakousis PC Int J Antimicrob Agents; 2014 Dec; 44(6):564-6. PubMed ID: 25270632 [TBL] [Abstract][Full Text] [Related]
15. Evaluation of nose-only aerosol inhalation chamber and comparison of experimental results with mathematical simulation of aerosol deposition in mouse lungs. Nadithe V; Rahamatalla M; Finlay WH; Mercer JR; Samuel J J Pharm Sci; 2003 May; 92(5):1066-76. PubMed ID: 12712427 [TBL] [Abstract][Full Text] [Related]
16. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations. API Consensus Expert Committee J Assoc Physicians India; 2006 Mar; 54():219-34. PubMed ID: 16800350 [TBL] [Abstract][Full Text] [Related]
17. Inhalation Study of Mycobacteriophage D29 Aerosol for Mice by Endotracheal Route and Nose-Only Exposure. Liu KY; Yang WH; Dong XK; Cong LM; Li N; Li Y; Wen ZB; Yin Z; Lan ZJ; Li WP; Li JS J Aerosol Med Pulm Drug Deliv; 2016 Oct; 29(5):393-405. PubMed ID: 26745146 [TBL] [Abstract][Full Text] [Related]
18. Altered expression of isoniazid-regulated genes in drug-treated dormant Mycobacterium tuberculosis. Karakousis PC; Williams EP; Bishai WR J Antimicrob Chemother; 2008 Feb; 61(2):323-31. PubMed ID: 18156607 [TBL] [Abstract][Full Text] [Related]
19. Poly (DL-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis. Pandey R; Sharma A; Zahoor A; Sharma S; Khuller GK; Prasad B J Antimicrob Chemother; 2003 Dec; 52(6):981-6. PubMed ID: 14613962 [TBL] [Abstract][Full Text] [Related]
20. Inhalable microparticles containing drug combinations to target alveolar macrophages for treatment of pulmonary tuberculosis. Sharma R; Saxena D; Dwivedi AK; Misra A Pharm Res; 2001 Oct; 18(10):1405-10. PubMed ID: 11697465 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]